L-glutamate is the major excitatory neurotransmitter in the central nervous system. The glutamate system represents an attractive molecular target in the treatment of epilepsy, neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease, Huntington’s chorea), schizophrenia, ischemia, pain, alcoholism and mood disorders[1].
Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) is an artificial glutamate analogue. Its receptor (originally named quisqualate receptor) is a non-NMDA-type ionotropic transmembrane receptor for glutamate that mediates fast synaptic transmission in the central nervous system. Like all ionotropic glutamate receptors, it consists of tetramers of four different types of subunits (GluR1-GluR4). The AMPA receptor GluA2 (GluR2) tetramer was the first and currently only glutamate receptor ion channel to be crystallized[2].
Kainate, a natural product, is an excitotoxic glutamate analogue produced by an algae, while NMDA is N-methyl-d-aspartate. Although all three glutamate receptor subtypes respond to glutamate, they can be distinguished by their response to these artificial agonists. Their distribution in the brain, physiological function, and mechanism and kinetics of activation and regulation are very different[3]. In two ways, the NMDA receptor is distinct from the other LGICs. First, it is both ligand-gated and voltage-dependent. Second, it requires co-activation by two ligands: glutamate and either d-serine or glycine. What’s more, the receptor controls a cation channel that is highly permeable to multiple monovalent ions and calcium[4]

[1] Molecular structure of ionotropic glutamate receptors. A.A. Kaczor, D. Matosiuk. Curr Med Chem. 2010,17, 2608-2635.
[2] AMPA receptors as drug targets in neurological disease--advantages, caveats, and future outlook. P.K. Chang, D. Verbich, R.A. McKinney. Eur. J. Neurosci. 2012, 35, 1908-1916.
[3] Kainate receptors. P. Pinheiro, C. Mulle. Cell and Tissue Research. 2006, 326, 457-482.
[4] The Role of N-Methyl-D-Aspartate (NMDA) Receptors in Pain: A Review. A.B. Petrenko et al. Anest. Analg. 2003, 97, 1108-1116

20 Item(s)

per page
Axon ID Name Description From price
3335 AZD6765 dihydrochloride Noncompetitive NMDA antagonist €90.00
4169 CIQ First NMDA NR2C/NR2D PAM €130.00
2254 CP 101606 NMDA NR2B antagonist €120.00
1406 CP 101606 mesylate NMDA NR2B antagonist €85.00
3841 Dextromethorphan hydrobromide Noncompetitive NMDA receptor antagonist €60.00
1246 Eliprodil NMDA antagonist €90.00
1262 Gavestinel NMDA antagonist (glycine site) €110.00
1156 Ifenprodil L-(+)-tartrate NMDA antagonist €55.00
1353 Lamotrigine Glutamate antagonist; Na+ channel blocker €60.00
1249 N 20C hydrochloride NMDA antagonist €85.00
3472 NMDA Selective NMDA agonist €60.00
3349 NMDAR-TRPM4 blocker C19 dihydrochloride NMDAR/TRPM4 interaction interface inhibitor €130.00
3348 NMDAR-TRPM4 blocker C8 dihydrochloride NMDAR/TRPM4 interaction interface inhibitor €120.00
1434 RGH 896 NMDA NR2B antagonist €95.00
3499 Riluzole Glutamatergic neurotransmission blocker; neuroprotectant €80.00
3576 Riluzole hydrochloride Glutamatergic neurotransmission blocker; neuroprotectant €80.00
1314 RO 25-6981 hydrochloride NMDA NR2B antagonist €110.00
2601 RO 25-6981 maleate NMDA NR2B antagonist €110.00
2708 TCN-201 NMDA NR2A antagonist €105.00
2261 ZD 9379 Antagonist of the glycine site on the NMDA receptor complex €95.00

20 Item(s)

per page
Please wait...